The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper

Autoimmunity Reviews

Volumn 13, Issue 7, 2014, Pages 751-755

  Fiorino, Gionata ^a   Girolomoni, Giampiero ^b   Lapadula, Giovanni ^c   Orlando, Ambrogio ^d   Danese, Silvio ^a   Olivieri, Ignazio ^e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT;

DERMATOLOGY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MEDICAL SOCIETY; REVIEW; RHEUMATOLOGY; ARTHRITIS, RHEUMATOID; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; ITALY; SKIN DISEASES;

ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLAMMATORY BOWEL DISEASES; ITALY; SKIN DISEASES; SOCIETIES, MEDICAL;

EID: 84898853424     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.02.004     Document Type: Review

References (46)

1. Wiens A., Venson R., Correr C.J., Otuki M.F., Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010, 30:339-353.
2. Bansback N., Sizto S., Sun H., Feldman S., Willian M.K., Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009, 219:209-218.
3. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
4. Bodger K., Kikuchi T., Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009, 30:265-274.
5. Liu Y., Wu E.Q., Bensimon A.G., Fan C.P., Bao Y., Ganguli A., et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012, 29:620-634.
6. Lapadula G., Ferraccioli G.F. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol 2012, 30:S102-S106.
7. Cuadrado M.J., Sciascia S., Bosch X., Khamashta M.A., Ramos-Casals M. Is it time for biosimilars in autoimmune diseases?. Autoimmun Rev 2013, 12:954-957.
8. European Medicine Agency Procedural advice for users of the centralised procedure for similar biological medicinal products applications 2011.
9. Weise M., Bielsky M.C., De Smet K., Ehmann F., Ekman N., Giezen T.J., et al. Biosimilars: what clinicians should know. Blood 2012, 120:5111-5117.
10. Ebbers H.C., Pieters T., Leufkens H.G., Schellekens H. Effective pharmaceutical regulation needs alignment with doctors. Drug Discov Today 2012, 17:100-103.
11. Weise M., Bielsky M.C., De Smet K., Ehmann F., Ekman N., Narayanan G., et al. Biosimilars-why terminology matters. Nat Biotechnol 2011, 29:690-693.
12. Comparability of biotechnological/biological products: note for guidance on biotechnological/biological products subject to changes in their manufacturing process. ICH Topic Q5E 2003.
13. European Medicine Agency Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues 2005, [EMA/CHMP/BWP/49348/2005].
14. European Medicine Agency Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 2005, [EMA/CHMP/BWP/42832/2005].
15. European Medicine Agency Procedural advice for users of the centralised procedure for similar bio-logical medicinal products applications 2013, [EMA/940451/2011].
16. Ebbers H.C., Crow S.A., Vulto A.G., Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012, 30:1186-1190.
17. Agenzia Italiana del Farmaco Position Paper sui farmaci biosimilari [Accessed on Feb, 2, 2014]. http://www.agenziafarmaco.gov.it/it/content/position-paper.
18. Agenzia Italiana del Farmaco Position paper sui farmaci biosimilari [Accessed on Sept. 29, 2013]. http://www.agenziafarmaco.gov.it/it/content/position-paper.
19. World Health Organization WHO informal consultation on International Nonproprietary Names (INN) policy for biosimilar products [Accessed on Dec, 2, 2013]. http://www.who.int/medicines/services/inn/inn_bio/en/index.html.
20. Yoo D.H., Prodanovic N., Jaworski J., Miranda P., Ramiterre E.B., Lanzon A., et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT [Accessed on Feb, 2, 2014]. http://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstracts?SearchString=biosimilar&Day=-1.
21. Park W., Miranda P., Brzosko M., Wiland P., Gutierrez-Ureña S., Lee Y.A., et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13 [Accessed on Feb, 02, 2014]. http://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/39201.
22. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?. AAPS J 2013, 16:22-26.
23. Yoo D.H., Hrycaj P., Miranda P., Ramiterre E., Piotrowski M., Shevchuk S., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.
24. Park W., Hrycaj P., Jeka S., Kovalenko V., Lysenko G., Miranda P., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013, 72:1605-1612.
25. Food and Drug Administration, Center for Drug Evaluation, Research (CDER), Center for Biologics Evaluation, Research (CBER) Guidance for industry. Non-inferiority clinical trials [Accessed on Dec 2, 2013]. http://www.fda.gov/downloads/Drugs//Guidances/UCM202140.pdf.
26. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005, 18:473-480.
27. World Health Organization Guidelines on evaluation of similar biotherapeutic products (SBPs) [Accessed on Dec 2, 2013]. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
28. Flood J. Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications. Manag Care 2009, 18:1-5.
29. Gisondi P., Cazzaniga S., Chimenti S., Giannetti A., Maccarone M., Picardo M., et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 2013, 27:e30-e41.
30. Lee H., Yim D.S., Zhou H., Peck C.C. Evidence of effectiveness: how much can we extrapolate from existing studies?. AAPS J 2005, 7:E467-E474.
31. Dranitsaris G., Amir E., Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 2011, 71:1527-1536.
32. European Medicine Agency Simponi: EPAR-summary for the public [Accessed on Feb, 2, 2014]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000992/human_med_001053.jsp&mid=WC0b01ac058001d124.
33. Peyrin-Biroulet L., Fiorino G., Buisson A., Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. Nat Rev Gastroenterol Hepatol 2013, 10:345-351.
34. European Medicines Agency Inflectra [Accessed on Sept. 29, 2013]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/smops/Positive/human_smop_000531.jsp&mid=WC0b01ac058001d127.
35. European Medicines Agency Remsima [Accessed on Sept. 29, 2013]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/smops/Positive/human_smop_000532.jsp&mid=WC0b01ac058001d127.
36. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
37. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
38. Sandborn W.J., Colombel J.F., Sands B.E., Rutgeerts P., Targan S.R., Panaccione R., et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012, 143:62-69. [e4].
39. Gecse K.B., Khanna R., van den Brink G.R., Ponsioen C.Y., Lowenberg M., Jairath V., et al. Biosimilars in IBD: hope or expectation?. Gut 2013, 62:803-807.
40. Danese S., Gomollon F. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013, 7:586-589.
41. Mikhail A., Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther 2013, 30:28-40.
42. Schneider C.K. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013, 72:315-318.
43. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
44. Isaacs J.D., Greenwood J., Waldmann H. Therapy with monoclonal antibodies. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J Immunol 1998, 161:3862-3869.
45. Li Y., Liu Q., Wood P., Johri A. Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins. Stat Med 2013, 32:393-405.
46. Mendes de Abreu M., Strand V., Levy R.A., Araujo D.V. Putting the value into biosimilar decision making: the judgment value criteria. Autoimmun Rev 2014, 13:678-684.